| scholarly article | Q13442814 |
| P2093 | author name string | Daniel W Nebert | |
| Ge Zhang | |||
| P2860 | cites work | Translating pharmacogenomics: challenges on the road to the clinic | Q21092371 |
| An integrated map of genetic variation from 1,092 human genomes | Q22122153 | ||
| Initial impact of the sequencing of the human genome | Q22122172 | ||
| Finding the missing heritability of complex diseases | Q22122198 | ||
| Genetic studies of body mass index yield new insights for obesity biology | Q22305005 | ||
| Are rare variants responsible for susceptibility to complex diseases? | Q22337172 | ||
| Genome-wide association studies for complex traits: consensus, uncertainty and challenges | Q24550632 | ||
| Complement factor H polymorphism in age-related macular degeneration | Q24553334 | ||
| Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a) | Q24594382 | ||
| Genetic variation in IL28B and spontaneous clearance of hepatitis C virus | Q24596340 | ||
| Pharmacogenomics knowledge for personalized medicine | Q24623166 | ||
| Hundreds of variants clustered in genomic loci and biological pathways affect human height | Q24630979 | ||
| CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network | Q24632735 | ||
| A genomewide association study of citalopram response in major depressive disorder | Q24656746 | ||
| Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity | Q24674721 | ||
| Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs | Q24683013 | ||
| Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker | Q36489410 | ||
| Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility | Q36498745 | ||
| Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to β-Blockers in Hypertensive African Americans | Q36576519 | ||
| Pharmacogenetics of warfarin: current status and future challenges | Q36597343 | ||
| Hypertension pharmacogenomics: in search of personalized treatment approaches | Q36652960 | ||
| PTPRD gene associated with blood pressure response to atenolol and resistant hypertension | Q36677516 | ||
| Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study | Q36730132 | ||
| Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01. | Q36762374 | ||
| Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2 | Q36828813 | ||
| A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose | Q36835176 | ||
| Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade | Q36853552 | ||
| Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges | Q36986507 | ||
| Are randomized trials obsolete or more important than ever in the genomic era? | Q36998698 | ||
| The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? | Q37029751 | ||
| Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. | Q37107608 | ||
| Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study | Q37138272 | ||
| Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide | Q37192199 | ||
| Clinical and pharmacogenetic factors associated with irinotecan toxicity | Q37192912 | ||
| Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic | Q37217719 | ||
| Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin | Q37222650 | ||
| Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans | Q37376879 | ||
| Pharmacogenomics of anticoagulants: steps toward personal dosage | Q37434634 | ||
| A pharmacogenetic versus a clinical algorithm for warfarin dosing | Q37616712 | ||
| Transporter pharmacogenetics and statin toxicity | Q37627544 | ||
| Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing | Q37652863 | ||
| Genome-wide association studies in pharmacogenomics. | Q37714294 | ||
| Uncovering the roles of rare variants in common disease through whole-genome sequencing | Q37755970 | ||
| Using genome-wide association studies to identify genes important in serious adverse drug reactions | Q37912159 | ||
| IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late? | Q37972766 | ||
| Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus? | Q38003338 | ||
| Insights from genome-wide association studies of drug response | Q38052588 | ||
| Genetic risk prediction: individualized variability in susceptibility to toxicants | Q38072103 | ||
| Advances in blood pressure genomics | Q38105530 | ||
| Bringing genome-wide association findings into clinical use. | Q38120138 | ||
| Genomic architecture of pharmacological efficacy and adverse events | Q38292930 | ||
| Genomic Clustering of differential DNA methylated regions (epimutations) associated with the epigenetic transgenerational inheritance of disease and phenotypic variation | Q36035307 | ||
| Clopidogrel: a case for indication-specific pharmacogenetics | Q36055186 | ||
| Genome-wide association study of warfarin maintenance dose in a Brazilian sample | Q36068687 | ||
| Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update | Q36084069 | ||
| The SLCO1B1*5 genetic variant is associated with statin-induced side effects | Q36158024 | ||
| Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers | Q36166107 | ||
| The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program | Q36181390 | ||
| Estimation of effect size distribution from genome-wide association studies and implications for future discoveries | Q36191121 | ||
| Pharmacogenomics and individualized drug therapy | Q36366823 | ||
| Improving postapproval drug safety surveillance: getting better information sooner | Q36367834 | ||
| Pharmacogenomics of human OATP transporters | Q36416907 | ||
| A global reference for human genetic variation | Q25909434 | ||
| Pharmacogenomics in the clinic | Q26782786 | ||
| Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States | Q26783092 | ||
| Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing | Q27008360 | ||
| Pharmacogenomics of adverse drug reactions | Q27015820 | ||
| Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe | Q28073630 | ||
| Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression | Q28116125 | ||
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
| Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin | Q28276514 | ||
| Biochemistry and molecular biology of the human CYP2C subfamily | Q28299258 | ||
| Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups | Q28395337 | ||
| A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose | Q28475004 | ||
| Unsolved challenges of clinical whole-exome sequencing: a systematic literature review of end-users' views | Q28597904 | ||
| Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis | Q28943549 | ||
| A mega-analysis of genome-wide association studies for major depressive disorder | Q29417093 | ||
| HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin | Q29417159 | ||
| Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index | Q29547208 | ||
| The future of genetic studies of complex human diseases | Q29547215 | ||
| Common SNPs explain a large proportion of the heritability for human height | Q29547221 | ||
| Rare and low-frequency coding variants alter human adult height | Q29583867 | ||
| Common genetic variation and human traits | Q29614445 | ||
| IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy | Q29614896 | ||
| Common and rare variants in multifactorial susceptibility to common diseases | Q29616282 | ||
| SLCO1B1 variants and statin-induced myopathy--a genomewide study | Q29619028 | ||
| Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C | Q29619541 | ||
| Transgenerational epigenetic inheritance in mammals: how good is the evidence? | Q30251679 | ||
| Best practices and joint calling of the HumanExome BeadChip: the CHARGE Consortium | Q30418185 | ||
| Review of statistical methodologies for the detection of parent-of-origin effects in family trio genome-wide association data with binary disease traits | Q30829290 | ||
| Estimation of the warfarin dose with clinical and pharmacogenetic data | Q33410725 | ||
| A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record | Q33419319 | ||
| A reference panel of 64,976 haplotypes for genotype imputation | Q33553419 | ||
| Using principal components of genetic variation for robust and powerful detection of gene-gene interactions in case-control and case-only studies | Q33708556 | ||
| Identification of Mendel's white flower character | Q33719190 | ||
| Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? | Q33818189 | ||
| Pitfalls of predicting complex traits from SNPs | Q33896815 | ||
| Gene--environment-wide association studies: emerging approaches | Q33937986 | ||
| The evolution of drug metabolism | Q34022352 | ||
| Oral anticoagulation: a critique of recent advances and controversies | Q38362468 | ||
| Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. | Q38460138 | ||
| Pharmacogenomics considerations in the control of hypertension | Q38629883 | ||
| Seventeen years of statin pharmacogenetics: a systematic review | Q38670109 | ||
| Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. | Q38682854 | ||
| Genotypic Context and Epistasis in Individuals and Populations | Q38897737 | ||
| Exploiting the potential of next-generation sequencing in genomic medicine | Q38940833 | ||
| Recent developments in understanding the mechanism of vitamin K and vitamin K-antagonist drug action and the consequences of vitamin K action in blood coagulation | Q39711465 | ||
| GT to AT transition at a splice donor site causes skipping of the preceding exon in phenylketonuria | Q40389149 | ||
| Adverse drug reactions: definitions, diagnosis, and management | Q40739350 | ||
| The Reliability of Psychiatric Diagnosis Revisited: The Clinician's Guide to Improve the Reliability of Psychiatric Diagnosis | Q41578593 | ||
| Genome-wide pharmacogenetics of antidepressant response in the GENDEP project | Q42655084 | ||
| Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese | Q42910090 | ||
| A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury | Q42966589 | ||
| Genomics: Hepatitis C virus gets personal | Q42991039 | ||
| Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. | Q43001792 | ||
| Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. | Q43844827 | ||
| Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction | Q44212606 | ||
| A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon | Q44473459 | ||
| A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. | Q45052744 | ||
| Is there clinical utility to IL28B genotype testing in the treatment of chronic hepatitis C virus infection? | Q45354882 | ||
| Pharmacogenetics and coumarin dosing--recalibrating expectations | Q45755696 | ||
| A genome-wide association study of acenocoumarol maintenance dosage. | Q45939541 | ||
| Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait. | Q46377291 | ||
| Factors influencing warfarin dose requirements in African-Americans | Q46885448 | ||
| ATM Regulates Adipocyte Differentiation and Contributes to Glucose Homeostasis. | Q50600930 | ||
| The initial field trials of DSM-5: new blooms and old thorns. | Q50729132 | ||
| The evidence dilemma in genomic medicine. | Q50769689 | ||
| A randomized trial of genotype-guided dosing of warfarin. | Q51140132 | ||
| Hints of hidden heritability in GWAS. | Q51814837 | ||
| CYP2D6 phenotype-specific codeine population pharmacokinetics. | Q53644957 | ||
| Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. | Q53655985 | ||
| PHARMACOGENETICS. | Q54070882 | ||
| Cloned human phenylalanine hydroxylase gene allows prenatal diagnosis and carrier detection of classical phenylketonuria | Q55062488 | ||
| Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study. | Q55070146 | ||
| HLA-B*38:02:01predicts carbimazole/methimazole-induced agranulocytosis | Q57273952 | ||
| Blood pressure pharmacogenomics | Q57315770 | ||
| From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions | Q60670847 | ||
| Human Leukocyte Antigen (HLA) Pharmacogenomic Tests: Potential and Pitfalls | Q63241907 | ||
| Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity | Q71571828 | ||
| Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications | Q73855996 | ||
| Warfarin-induced skin necrosis in a patient with a mutation of the prothrombin gene | Q74587483 | ||
| Genetic control of isoniazid metabolism in man | Q79227074 | ||
| Statistical power of association using the extreme discordant phenotype design | Q83365160 | ||
| Personalized medicine: temper expectations | Q84873108 | ||
| Pharmacogenetics of the human arylamine N-acetyltransferases | Q34022390 | ||
| Characterization of the common genetic defect in humans deficient in debrisoquine metabolism | Q34049056 | ||
| Defective N-oxidation of sparteine in man: A new pharmacogenetic defect | Q34053243 | ||
| Polymorphic hydroxylation of Debrisoquine in man. | Q34057031 | ||
| Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations | Q34065310 | ||
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | Q34117815 | ||
| Implementation and utilization of genetic testing in personalized medicine | Q34147916 | ||
| HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans | Q34172669 | ||
| The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. | Q34216710 | ||
| PM frequencies of major CYPs in Asians and Caucasians | Q34228441 | ||
| Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance | Q34241858 | ||
| Heterogeneity of phenylketonuria at the clinical, protein and DNA levels | Q34265187 | ||
| A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer | Q34392792 | ||
| Genome-wide association studies in pharmacogenomics: successes and lessons | Q34415006 | ||
| Defining the role of common variation in the genomic and biological architecture of adult human height | Q34441746 | ||
| Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins | Q34453666 | ||
| Progress and promise of genome-wide association studies for human complex trait genetics | Q34537519 | ||
| Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes | Q34539510 | ||
| The incidentalome: a threat to genomic medicine | Q34546699 | ||
| CYP4F2 genetic variant alters required warfarin dose | Q34746151 | ||
| Genome-based prediction of common diseases: advances and prospects | Q34851798 | ||
| Epigenetic inheritance and the missing heritability problem | Q34979321 | ||
| Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification | Q35087118 | ||
| Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss | Q35172741 | ||
| The decade of the epigenomes? | Q35216083 | ||
| CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma | Q35266066 | ||
| Distribution of allele frequencies and effect sizes and their interrelationships for common genetic susceptibility variants | Q35518379 | ||
| Rare and common variants: twenty arguments | Q35533255 | ||
| The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. | Q35715254 | ||
| A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression | Q35737324 | ||
| TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. | Q35794752 | ||
| Genome-wide analysis links NFATC2 with asparaginase hypersensitivity | Q35820373 | ||
| A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. | Q36013520 | ||
| P921 | main subject | personalized medicine | Q2072214 |
| P304 | page(s) | 75-90 | |
| P577 | publication date | 2017-02-14 | |
| P1433 | published in | Pharmacology & Therapeutics | Q3378596 |
| P1476 | title | Personalized medicine: Genetic risk prediction of drug response | |
| P478 | volume | 175 |
| Q89879213 | Direct-to-Consumer Nutrigenetics Testing: An Overview |
| Q64081974 | Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking Back on Treatments |
| Q47308561 | Perspective on the Genetic Response to Antiparasitics: A Review Article |
Search more.